创新药板块方面，上半年亿立舒累计发货超22万只，同比大幅增长96.02%，此外报告期内，亿立舒完 成向美国市场的首批发货，智通财经记者曾报道，该药物在美最终定价为4600美元/支，约为国内售价 的14倍。此外，公司继续推进亿立舒全球商业化合作。截至本报告披露日，公司已与正大天晴、 Acrotech等公司在中国和美国、德国、奥地利等超40个国家达成商业合作，实现在34个国家或地区获批 上市销售，在5个国家实现发货或销售。 智通财经8月14日讯（记者 何凡）H1亿帆医药（002019.SZ）旗下首个创新生物药亿立舒（艾贝格司亭α 注射液）陆续在包括美国在内的5个国家实现商业化发货或销售，公司创新药板块营收快速增长。叠加 医药自有（含进口）板块业务的同比增长，今年上半年亿帆医药归母净利润提升近两成。 今日晚间，亿帆医药披露2025年半年报，H1公司实现营业收入26.35亿元，同比增长0.11%；归母净利 润3.04亿元，同比增长19.91%。依此计算，Q2公司实现归母净利润1.50亿元，同比增长40.48%。 公司方面表示，主要业绩驱动因素为，报告期内，公司药品制剂业务以突出自有产品为主，同时集中医 学推广和渠道等 ...

Group 1: Financial Performance - In 2024, the company reported a revenue of 2.971 billion yuan, a decrease of 18.06% year-on-year, and a net loss of 1.329 billion yuan, with a decline of 2920.55% [32] - The net cash flow from operating activities in 2024 was -149.8 million yuan, an improvement of 39.87% compared to -249 million yuan in the previous year [11] - In Q1 2025, the company achieved total revenue of 755 million yuan, a decrease of 3.53% year-on-year, while the net profit attributable to shareholders was 1.1572 million yuan, down 94.99% [14] Group 2: Market Strategy and Product Development - The company plans to enhance its market presence by focusing on product innovation, efficiency improvement, and structural optimization to achieve sustainable development [12] - In 2024, the company launched new products such as hair growth capsules and white blood cell-enhancing granules, with plans for continued expansion in 2025 [12] - The company aims to improve its market share for core products, including the compound Ku Shen injection and Minoxidil lotion, which has a market share of 47.3% [25] Group 3: Response to Industry Challenges - The company is adapting to industry challenges such as centralized procurement and medical insurance cost control by optimizing its product structure and focusing on high-value drugs [10] - The company has implemented measures to improve cash flow, including better management of accounts receivable and reducing long payment terms in wholesale business [11] - The company is continuously monitoring market dynamics and adjusting strategies to ensure stable growth despite external pressures [15] Group 4: R&D and Innovation - In 2024, the company invested 251 million yuan in R&D, a year-on-year increase of 25.27%, focusing on innovative drugs and modern traditional Chinese medicine [18] - The company has established a new drug creation center in Shanghai and initiated clinical research for new anti-tumor drugs [18] - The company is committed to enhancing its R&D capabilities and has made significant progress in various projects, including the registration of traditional Chinese medicine with the FDA [18] Group 5: Corporate Governance and Investor Relations - The company is implementing a share repurchase plan, having repurchased 51.025 million yuan worth of shares by April 30, 2025, which will be included in the cash dividend calculation [4] - The company emphasizes transparency and will disclose any significant developments regarding acquisitions and financial management in accordance with legal requirements [12] - The company acknowledges investor concerns regarding stock performance and is focused on improving operational efficiency and communication with the market [3]

Group 1 - The core viewpoint of the news is that Shanxi Zhendong Pharmaceutical Co., Ltd. reported significant financial growth in 2024, achieving an operating income of 2.971 billion yuan and a turnaround in profit for Q1 2025 with a net profit of 28,960 yuan, marking a year-on-year increase of 103.37% [1] - In 2024, the company's key products, including Yanshu Compound Sophora Injection and Dafeixin Minoxidil Lotion, maintained steady growth, with the former leading in usage among similar drugs for three consecutive years and the latter achieving a market share of 47.3% [1] - The company expanded its product offerings in 2024 with new selections in the centralized procurement process, including Du Yi Wei Granules and Dengzhanhua Dispersible Tablets, which are expected to significantly boost sales in grassroots markets [1] Group 2 - In the innovative drug sector, the company completed the efficacy evaluation of a new skin drug and initiated clinical trials for an innovative traditional Chinese medicine, ZD16, while also starting preclinical research for an anti-tumor new drug [2] - The company is advancing 30 raw material drug projects and 31 formulation projects, including the FDA registration of Yanshu and research on its efficacy for pancreatic cancer [2] - A collaboration was signed with Westlake University and Beijing Natural Intelligence Pharmaceutical Technology Co., Ltd. to modernize the research and development of traditional Chinese medicine using AI technology [2]